Regulatory Affairs Professionals Society
Executive Summary
Keynote speaker at RAPS' annual meeting Sept. 13-14 in Washington is FDA Deputy Com. Novitch, who will speak on the development of agency action plans for the next decade and beyond. "Regulatory Perspectives" panel moderated by D.C. attorney James Phelps will include six officials from the agency's Centers for Drugs & Biologics and for Devices & Radiological Health. Workshop on ANDA/Patent Restoration bill will feature Milton Bass (Bass Ullman & Lustigman); PMA counsel Neil Mulcahy; and Natl. Assn. of Pharmaceutical Mfrs. Exec Director George Schwartz
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.